Summary
Vertex Pharmaceuticals Inc. (VRTX) filed an 8-K on May 5, 2022, primarily to report its financial results for the first quarter ended March 31, 2022. The company issued a press release detailing these results, which is attached as an exhibit. A significant change in reporting is the inclusion of research and development charges from collaborations, asset acquisitions, and licensing in their Non-GAAP financial measures starting in Q1 2022. Previously excluded, these costs will now be part of Non-GAAP net income and earnings per share calculations. To ensure comparability, Vertex has also recast its 2021 Non-GAAP financial statements to reflect this updated methodology.
Key Highlights
- 1Vertex Pharmaceuticals reported its Q1 2022 financial results via a press release filed on May 5, 2022.
- 2The company has updated its Non-GAAP reporting methodology to include R&D charges from collaborations, asset acquisitions, and licensing.
- 3These R&D charges were previously excluded from Non-GAAP measures but will be included starting Q1 2022.
- 4Vertex has restated its 2021 Non-GAAP financial results (quarterly and full-year) to align with the new reporting standard.
- 5The press release and recast financial data are incorporated by reference via attached exhibits.
- 6The filing does not contain new operational developments beyond the financial reporting update and recasting of prior periods.